TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35612617

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 12 sessions of an exercise protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication group (MG) - Oral dose of UC-II (1 capsule/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG) - No intervention
Number of subjects: 0
Study: 34620904

Group type: EXPERIMENTAL
Intervention: Active mouthwash (APD) - gargling/rinsing 5 times/day until hospital discharge
Number of subjects: 41

Group type: COMPARATOR
Intervention: Nonactive mouthwash (control) - gargling/rinsing 5 times/day until hospital discharge
Number of subjects: 41
Study: 36204964

Group type: EXPERIMENTAL
Intervention: Digital impression combined with all-ceramic denture restoration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Silicone rubber impression combined with all-ceramic denture restoration
Number of subjects: 120
Study: 33530312

Group type: EXPERIMENTAL
Intervention: Daily oral treatment with 3 g Clostridium butyricum
Number of subjects: 20

Group type: COMPARATOR
Intervention: No probiotic treatment
Number of subjects: 20
Study: 32303745

Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 fatty acid serum concentrations
Number of subjects: 200
Study: 36153514

Group type: EXPERIMENTAL
Intervention: Intervention group (community-based intervention to increase intergenerational contact)
Number of subjects: 2518

Group type: COMPARATOR
Intervention: Control group (public health services as usual)
Number of subjects: 2518
Study: 33845931

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 36152791

Group type: EXPERIMENTAL
Intervention: Self-guided health education (SGHE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventionist-guided health education (IGHE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventionist-guided pain coping skills training (CST-PSP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 35831874

Group type: EXPERIMENTAL
Intervention: Fluralaner (oral dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 28
Study: 34413142

Group type: EXPERIMENTAL
Intervention: Hyoscine N‐butylbromide (20 mg intravenous injection)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg per os)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 18F‐4FMFES
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 18F‐FDG
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of 18F‐4FMFES and 18F‐FDG
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of grade 1 and higher-grade tumors
Number of subjects: 25
Study: 35141317

Group type: EXPERIMENTAL
Intervention: Hypnosis (4-week group PRP supplemented by two educational sessions for self-hypnosis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation (4-week group PRP supplemented by standard relaxation exercises)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0
Study: 36322475

Group type: EXPERIMENTAL
Intervention: Dissolved tablet (BIC/TAF/FTC 50/200/25 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Crushed tablet (BIC/TAF/FTC 50/200/25 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Solid tablet (BIC/TAF/FTC 50/200/25 mg)
Number of subjects: 18
Study: 33496795

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Bicalutamide (50 mg daily)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg daily) among Black patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Bicalutamide (50 mg daily) among Black patients
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg daily) among non-Black patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Bicalutamide (50 mg daily) among non-Black patients
Number of subjects: 71
Study: 32112428

Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream (treatment group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Plain petri dishes (control group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Observational study (30 scabies mites)
Number of subjects: 70
Study: 34599979

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 weeks for the first 3 doses, then every 8 weeks thereafter
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 32871885

Group type: EXPERIMENTAL
Intervention: Critical Thinking Intervention (CTI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 44
Study: 35179608

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual trigger point pressure release
Number of subjects: 50
Study: 33964405

Group type: EXPERIMENTAL
Intervention: Intradiscal ozone infiltration (plus foraminal infiltration of ozone, steroids, and anesthetic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intradiscal oxygen infiltration (plus foraminal infiltration of oxygen, steroids, and anesthetic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intradiscal ozone infiltration
Number of subjects: 0
Study: 32299068

Group type: EXPERIMENTAL
Intervention: RCMFE of the CP signal in glaucomatous eyes
Number of subjects: 58

Group type: COMPARATOR
Intervention: RCMFE of the CP signal
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Optimal scale for RCMFE
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis for optimal scale
Number of subjects: 58
Study: 35260800

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 1762
Study: 33934120

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance (CO‐OP) intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 78
Study: 35118746

Group type: EXPERIMENTAL
Intervention: Specific Thematic Nursing Care Action Modules (STNC‐AM)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 32893100

Group type: EXPERIMENTAL
Intervention: Kinesio tape
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard protocol (cockup orthosis and lumbrical stretching exercises)
Number of subjects: 44
Study: 36494919

Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 17
Study: 34058081

Group type: EXPERIMENTAL
Intervention: 800 mg dipyrone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 50 mg tilidine/naloxone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 100 mg tilidine/naloxone
Number of subjects: 260

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 260
Study: 32746736

Group type: EXPERIMENTAL
Intervention: Yoga meditation program (YoMed)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Established proprioceptive training program (PRO)
Number of subjects: 33
Study: 33052906

Group type: EXPERIMENTAL
Intervention: Competitive gamification intervention
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Supportive gamification intervention
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Collaborative gamification intervention
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 602
Study: 32804602

Group type: EXPERIMENTAL
Intervention: Workplace Health Promotion Program (WHPP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 32050899

Group type: EXPERIMENTAL
Intervention: G-MEDSS intervention (Computerised Clinical Decision Support System)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care HMR service (without G-MEDSS)
Number of subjects: 0
Study: 36180151

Group type: EXPERIMENTAL
Intervention: Pilates exercises for 6 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual antenatal care (control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pilates exercises
Number of subjects: 21
Study: 34627156

Group type: EXPERIMENTAL
Intervention: Video-based teaching
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Simulation-based teaching
Number of subjects: 153

Group type: COMPARATOR
Intervention: Lecture-based teaching (control)
Number of subjects: 153
Study: 34935067

Group type: COMPARATOR
Intervention: Locator
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CM LOC
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PEKK
Number of subjects: 17
Study: 33630448

Group type: EXPERIMENTAL
Intervention: Multi-port laparoscopic colectomy (MPC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single-incision laparoscopic colectomy (SILC)
Number of subjects: 200
Study: 35588245

Group type: EXPERIMENTAL
Intervention: Viloxazine extended-release (600 mg/d)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 33648496

Group type: EXPERIMENTAL
Intervention: ICF training programme (one day's training in interprofessional practice)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Short talk on interprofessional practice (control group)
Number of subjects: 203
Study: 35654318

Group type: EXPERIMENTAL
Intervention: Losartan (LT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 32701452

Group type: EXPERIMENTAL
Intervention: Deep belief network (DBN) for classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stacked denoising autoencoder (SDA) for reconstruction of handwritten digits
Number of subjects: 0
Study: 32768465

Group type: EXPERIMENTAL
Intervention: Enalapril (initial dose 0.10 mg/kg/d, median maximal dose 0.38 mg/kg/d)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230
Study: 35019882

Group type: EXPERIMENTAL
Intervention: Yoga exercise program (one hour twice weekly for 12 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Patient education program (for both groups)
Number of subjects: 48
Study: 34814768

Group type: EXPERIMENTAL
Intervention: Warm water plus ginger (GI)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Warm water plus mustard (MU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Warm water only (WA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Skin temperature measurements (face, hands, feet)
Number of subjects: 36
Study: 35881199

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) eyedrops, applied 4 times daily for 2 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Semi‐fluorinated alkane (SFA) eyedrops, applied 4 times daily for 2 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (non-smokers)
Number of subjects: 78
Study: 34362491

Group type: EXPERIMENTAL
Intervention: HOTAIRM1 siRNA group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: HOTAIRM1 siRNA-NC group
Number of subjects: 0
Study: 33068876

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: siRNA depletion in a human trophoblast cell line model
Number of subjects: 43

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 43
Study: 33190178

Group type: EXPERIMENTAL
Intervention: TRUST intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Time and attention control
Number of subjects: 200
Study: 36564573

Group type: EXPERIMENTAL
Intervention: Subcision combined with cross-linked HA filler injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcision followed by fractional CO2 laser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcision only (control group)
Number of subjects: 40
Study: 32144616

Group type: EXPERIMENTAL
Intervention: ACT self-help
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enhanced self-help (ACT self-help with telephone support)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 33539400

Group type: EXPERIMENTAL
Intervention: Self-Administered therapy (SAT)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 252
Study: 32320027

Group type: EXPERIMENTAL
Intervention: Clascoterone cream, 1%
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 1440
Study: 36165956

Group type: EXPERIMENTAL
Intervention: Systemic acupuncture associated with pelvic floor muscle training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pelvic floor muscle training only
Number of subjects: 64
Study: 33668674

Group type: EXPERIMENTAL
Intervention: Cheddar cheese (20 g protein)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Milk (isonitrogenous amount)
Number of subjects: 24
Study: 35006081

Group type: EXPERIMENTAL
Intervention: NoHoW Toolkit (TK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 33337657

Group type: EXPERIMENTAL
Intervention: Inreach plus mailed outreach
Number of subjects: 12386

Group type: COMPARATOR
Intervention: Inreach alone
Number of subjects: 12386
Study: 35565914

Group type: EXPERIMENTAL
Intervention: Endurance training during rehabilitation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no endurance training)
Number of subjects: 32
Study: 35649684

Group type: EXPERIMENTAL
Intervention: Explicit sensory retraining (ESR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Implicit repeated exposure (IRE)
Number of subjects: 64
Study: 35369650

Group type: EXPERIMENTAL
Intervention: TMX-049 200 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: TMX-049 40 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: TMX-049 200 mg and 40 mg
Number of subjects: 130
Study: 32187663

Group type: EXPERIMENTAL
Intervention: Perianal block with ropivacaine
Number of subjects: 138
Study: 34807241

Group type: EXPERIMENTAL
Intervention: Ciclesonide MDI, 160 μg per actuation, 2 actuations twice a day (total daily dose, 640 μg) for 30 days
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 400
Study: 32897519

Group type: EXPERIMENTAL
Intervention: Bacillus clausii (Enterogermina®) capsules, 2 × 10^9 spores, three times daily for 2 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo, three times daily for 2 weeks
Number of subjects: 130
Study: 35325392

Group type: EXPERIMENTAL
Intervention: Tailored exercise protocol for CM (TEP‐CM)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cervical spinal stabilization exercises (CSSE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups (TEP‐CM and CSSE)
Number of subjects: 16
Study: 33637948

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 790

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 790
Study: 33126366

Group type: EXPERIMENTAL
Intervention: Internet-based rehabilitation group (IRG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study: 616410548

Group type: EXPERIMENTAL
Intervention: ipragliflozin (50 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: control group
Number of subjects: 62
Study: 35389028

Group type: EXPERIMENTAL
Intervention: Microneedling group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tranexamic acid group (TA 250 mg twice daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Microneedling and tranexamic acid group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study: 33682358

Group type: EXPERIMENTAL
Intervention: HLX03 (adalimumab biosimilar)
Number of subjects: 220

Group type: COMPARATOR
Intervention: CN-sourced adalimumab (control)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: HLX03
Number of subjects: 220
Study: 32646428

Group type: EXPERIMENTAL
Intervention: Trehalose (3.3 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sucrose (3.3 g/day)
Number of subjects: 50
Study: 36369671

Group type: EXPERIMENTAL
Intervention: Survivorship care plans (SCPs) delivery arms
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 316
Study: 35320642

Group type: EXPERIMENTAL
Intervention: Single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day)
Number of subjects: 814

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control)
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Single high dose of liposomal amphotericin B
Number of subjects: 814

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (control)
Number of subjects: 814
Study: 34129085

Group type: EXPERIMENTAL
Intervention: Maxillary middle meatal antrostomy (MMMA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (MMMA + frontal sinusotomy)
Number of subjects: 40
Study: 34160597

Group type: EXPERIMENTAL
Intervention: Absorbable antibiotic eluting envelope
Number of subjects: 0
Study: 32912989

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 0
Study: 32571414

Group type: EXPERIMENTAL
Intervention: Double layer tragal cartilage‐perichondrium graft (Group A)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Temporal muscle fascia graft (Group B)
Number of subjects: 134
Study: 35882466

Group type: EXPERIMENTAL
Intervention: Digital multiple health behaviour change intervention components (goal setting, increasing motivation, etc.)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (no intervention components)
Number of subjects: 1500
Study: 33475824

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab
Number of subjects: 149

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 149
Study: 32307155

Group type: EXPERIMENTAL
Intervention: Oral electrolyte solution (OES) administered in milk replacer (MR) and water (3 L at 1300 and 2200 h) for 4 d
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CON) receiving a small dose of whey (n = 12)
Number of subjects: 45
Study: 33550525

Group type: EXPERIMENTAL
Intervention: Device-aided therapies (CSAI, LCIG, DBS)
Number of subjects: 44
Study: 32157765

Group type: EXPERIMENTAL
Intervention: Cream A (without tranexamic acid)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cream B (with tranexamic acid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream (Group C)
Number of subjects: 60
Study: 36166328

Group type: EXPERIMENTAL
Intervention: Trauma condition (listening to a depiction of sexual assault)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control condition (listening to a similar experience without sexual assault)
Number of subjects: 105
Study: 32665506

Group type: EXPERIMENTAL
Intervention: Procedural sedoanalgesia (PSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultrasound-guided infraclavicular block (ICB)
Number of subjects: 60
Study: 32938411

Group type: EXPERIMENTAL
Intervention: Drug Sensitive TB (DS-TB) treatment
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Multi Drug Resistant Tuberculosis (MDR TB) treatment
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: General TB treatment
Number of subjects: 1178
Study: 36004384

Group type: EXPERIMENTAL
Intervention: Dynamic orthosis (night-worn for one year)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Serial casting (four weeks followed by night splinting)
Number of subjects: 55
Study: 34107529

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 20
Study: 32053141

Group type: EXPERIMENTAL
Intervention: Injection of autologous adipose tissue-derived stromal vascular fraction (ADSVF) into 1 or 2 vocal folds.
Number of subjects: 8
Study: 35344012

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 32
Study: 33903287

Group type: EXPERIMENTAL
Intervention: Direct-acting oral anticoagulants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional anticoagulants
Number of subjects: 0
Study: 36269738

Group type: EXPERIMENTAL
Intervention: Web-based parenting program entitled 'Making a healthy deal with your child'
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control condition (existing schoolclass‐based overweight prevention program)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Web-based parenting program
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 475
Study: 33675348

Group type: EXPERIMENTAL
Intervention: 5 mg resveratrol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 g resveratrol
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resveratrol in vitro
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resveratrol metabolites (mono-sulfates and glucuronides)
Number of subjects: 30
Study: 34614330

Group type: EXPERIMENTAL
Intervention: Immediate drainage within 24 hours after randomization
Number of subjects: 104

Group type: COMPARATOR
Intervention: Postponed drainage until walled-off necrosis was reached
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Immediate drainage
Number of subjects: 104

Group type: COMPARATOR
Intervention: Postponed drainage
Number of subjects: 104
Study: 34971581

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a in MPN-RC 111
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a in MPN-RC 112
Number of subjects: 280

Group type: COMPARATOR
Intervention: hydroxyurea in MPN-RC 112
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a
Number of subjects: 280

Group type: COMPARATOR
Intervention: hydroxyurea
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: complete and partial responders
Number of subjects: 280
Study: 32934137

Group type: EXPERIMENTAL
Intervention: Pegloticase in combination with Methotrexate (MTX)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pegloticase alone (previously reported)
Number of subjects: 14